Copyright
©2014 Baishideng Publishing Group Co.
World J Crit Care Med. Feb 4, 2014; 3(1): 24-33
Published online Feb 4, 2014. doi: 10.5492/wjccm.v3.i1.24
Published online Feb 4, 2014. doi: 10.5492/wjccm.v3.i1.24
Table 1 Overview of the analogy of prescribing fluid therapy and prescribing a drug
Steps for prescribing a drug | Prescribing an oral hypoglycemic medication | Prescribing fluid therapy |
Define the clinical problem | Diabetes mellitus | Hypovolemia or other fluid responsive state |
Specify the therapeutic objective | Lower blood glucose | Restore absolute/relative fluid deficit |
Verify the suitability of the drug | Class of oral hypoglycemic agent | Crystalloid, colloid or blood product |
Write a prescription to start the drug | Order written by MD, verified and dispensed by pharmacy | Order written by MD, verified by pharmacy, blood bank or RN, administered by RN |
Monitor therapeutic response of the drug | Blood glucose or hemoglobin A1C, evidence of adverse effect/ toxicity | Monitor hemodynamic profile and end-organ perfusion, evidence of dose-response toxicity |
Write an order to discontinue | Order written by MD, verified by pharmacy | Order written by MD, administered by RN |
Table 2 Summary of studies comparing isotonic saline to balanced crystalloid solutions
Study | Design | Population | Solutions | Outcome |
McFarlane et al[59] | RCT | Elective hepatobiliary/pancreatic surgery | 0.9% saline vs PL-148 | Iatrogenic metabolic acidosis with 0.9% saline |
Wilkes et al[47] | RCT | Major abdominal surgery | 0.9% saline vs Hartmann's (in HES) | Iatrogenic metabolic acidosis with 0.9% saline |
O'Malley et al[48] | RCT | Kidney transplant recipients | 0.9% saline vs RL | Iatrogenic metabolic acidosis and hyperkalemia with 0.9% saline |
Yunos et al[56] | Prospective before-and-after | Critically ill patients | Chloride-rich vs chloride-poor fluid strategy | More acidosis with chloride-rich; more alkalosis and reduced cost with chloride-poor |
Chowdbury et al[26] | RCT (cross-over) | Healthy volunteers | 0.9% saline vs PL-148 (2 L infusion) | ↑Δ [Cl-]; ↑ Strong ion difference; ↓ RBF; ↑ weight gain; ↑ extravascular volume; ↑ time to micturation |
Chua et al[49] | Retrospective | Critically ill with DKA | 0.9% saline vs PL-148 | More rapid resolution of acidosis with PL-148 |
Shaw et al[55] | Retrospective | Major abdominal surgery | 0.9% saline vs PL-148 | ↑ Major infection; ↑ composite of complications; ↑ blood transfusions; and ↑ RRT with 0.9% saline |
Yunos et al[57] | Prospective before-and-after | Critically ill patients | Chloride-rich vs chloride-poor fluid strategy | ↑ AKI (KDIGO stage II/III); ↑ RRT with chloride-rich strategy |
Table 3 Studies in critically ill patients describing the association with fluid overload and worse outcome
Study | Design | Population | Exposures | Outcomes |
Pediatric Studies | ||||
Goldstein et al[33] | Retrospective | Pediatric critically ill starting CRRT | % FO | ↑ % FO associated with ↑ mortality |
Foland et al[60] | Retrospective | Pediatric critically ill starting CRRT | % FO | ↑ % FO associated with ↑ organ dysfunction + mortality |
Sutherland et al[31] | Retrospective | Pediatric critically ill starting CRRT | % FO | ↑ % FO associated with ↑ mortality |
Arikan et al[30] | Retrospective | Pediatric critically ill starting CRRT | % FO | ↑ % FO associated with ↓ lung function |
Adult Studies | ||||
Payen et al[61] | Post-hoc prospective | Adult critically ill septic patients | FB | ↑ FB associated with ↑ mortality |
Murphy et al[62] | Retrospective | Adult critically ill ALI patients | AIFR + CLFM | ↑ Survival for ↑ AIFR + ↑ CLFM |
Bouchard et al[63] | Post-hoc prospective | Adult critically ill AKI patients | % FO > 10% | ↑ FB associated with ↑ mortality |
Wiedemann et al[36] | RCT | Adult critically ill with ALI | Conservative vs liberal fluid management strategy | ↑ MV-free days; ↑ ICU-free days with conservative strategy |
Fulop et al[64] | Retrospective | Adult critically ill starting CRRT | VRWG | ↑ VRWG associated with ↑ mortality |
Boyd et al[65] | Post-hoc analysis from VASST | Adult critically ill septic patients | Quartiles of FB + CVP at 12 h and 4 d | ↑ FB at 12 h and 4 d associated with ↑ mortality; CVP < 8 at 12 h ↓ mortality |
Grams et al[66] | Post-hoc FACCT | Adult critically ill with ALI + AKI | FB + diuretics | ↑ FB associated with ↑ mortality |
Heung et al[67] | Retrospective | Adult critically ill starting CRRT | % FO | ↑ % FO associated with ↓ kidney recovery |
Bellomo et al[68] | Post-hoc RENAL | Adult critically ill with AKI | FB | ↑ FB associated with ↑ mortality |
Table 4 Summary of randomized trials of hydroxyethyl starch resuscitation in severe sepsis/septic shock and kidney outcomes
Ref. | RCT type | n(HES/CON) | Population (n) | HES fluid | Control fluid | Kidney parameters | RRT (OR; 95%CI) |
Schortgen et al[50] | Multi-centre | 129 (65/64) | Severe sepsis/ septic shock | 6% (200/0.62) | 3% gelatin | ↑ AKI ↑ oliguria, ↑ peak SCr | 1.20 (0.5-2.9) |
Molnár et al[69] | Single centre | 30 (15/15) | Septic shock | 6% (200/0.60) | 3% gelatin | NR | NR |
McIntyre et al[70] | Multi-centre | 40 (21/19) | Septic shock | 6% (200/0.50) | 0.9% NS | No difference | 3.00 (0.3-31.6) |
Brunkhorst et al[42] | Multi-centre | 537 (262/275) | Severe sepsis/septic shock | 10% (200/0.5) | RL | ↑ AKI | 1.95 (1.3-2.9) |
Guidet et al[23] | Multi-centre | 196 (100/96) | Severe sepsis/septic shock | 6% (130/0.4) | 0.9% NS | No difference | NR |
Perner et al[6] | Multi-centre | 798 (398/400) | Severe sepsis/septic shock | 6% (130/0.42) | Ringer’s acetate | ↑ AKI | 1.35 (1.01-1.8) |
Myburgh et al[5] | Multi-centre | 7000 (3315/3336) | Sepsis (27.4%) (1921/7000) | 6% (130/0.4) | 0.9% NS | ↑ RRT | 1.21 (1.00-1.45) |
- Citation: McDermid RC, Raghunathan K, Romanovsky A, Shaw AD, Bagshaw SM. Controversies in fluid therapy: Type, dose and toxicity. World J Crit Care Med 2014; 3(1): 24-33
- URL: https://www.wjgnet.com/2220-3141/full/v3/i1/24.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v3.i1.24